CSL has taken a profit hit thanks to higher plasma collection costs and Vifor deal expenses, but revenue rose 19 per cent to $US7.2 billion in the first half thanks to the performance of its core immunoglobulin business.
Australia's CSL Says 1st Half Profit Steady at Constant Currency morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.